EAPB0503

EAPB0503 is a quinoline compound with anti-tumor activity, showing strong cytotoxicity against melanoma cells in vitro (IC50=200 nM) . EAPB0503 can induce specific cell cycle arrest in mitosis of CML cells and directly activate apoptosis, leading to an increase in the G0 cell population, disruption of mitochondrial membrane potential, PARP cleavage, and DNA fragmentation. EAPB0503 also reduces the levels of BCR-ABL protein [1] [2].

Product Specifications

CAS Number

[1140627-77-5]

UNSPSC

12352005

Target

Apoptosis; Bcr-Abl; Mitosis; PARP

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

COC1=CC(C2=CN=C3N2C4=C(C=CC=C4)N=C3NC)=CC=C1

Molecular Formula

C18H16N4O

Molecular Weight

304.35

References & Citations

[1]Sonia Khier, et al. Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. J. Sep. Sci. 2009, 32, 1363-1373.|[2]Jessica Saliba, et al. EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anticancer Drugs. 2014 Jul;25 (6) :624-32.